# GENE1:1

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gene1-1

- Industry: Healthcare
- Headquarters: Seoul, South Korea
- Website: www.gene1on1.com
- Total disclosed funding: $0M
- Latest round: Seed (Nov 15, 2022)
- Investors on record: 1

## About

Founded in 2019 and based in Seoul, South Korea, JinOneOnOne Co., Ltd., dba GENE1:1, operates as a provider of intestinal microbe diagnostic services and products. As of February 2023, Jinyoung Lee serves as the CEO of the company. In November 2022, JinOneOnOne Co., Ltd. raised KRW 50 million in seed funding from CNTTech.

The company provides digital healthcare based on both beneficial and toxic bacteria (microbiomes) of intestinal microbes. The firm offers mental health microbes such as phacalibacterium, flavonifractor, coprococcus, dialister, blautia, and permicutes. The company also offers a service that recommends supplements and meal plans based on intestinal microbial tests. GENE1:1’s partners include Futureplay, Future’s Lab, Geninus, MLAI, and more.

## Funding rounds

- Seed, Nov 15, 2022 — CNT Tech
- Seed, Aug 20, 2019, $0M — CNT Tech

## Investors

- CNT Tech (https://capitalatlas.ai/funds/cnt-tech) — Seed